Navigation Links
Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
Date:1/8/2009

SOUTH SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today provided an overview of its 2009 clinical goals for development of picoplatin, its lead product candidate. Picoplatin is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. It is currently being evaluated in a Phase 3 registrational trial (SPEAR or Study of Picoplatin Efficacy After Relapse) in small cell lung cancer (SCLC), and in Phase 2 clinical trials as a first-line chemotherapy in colorectal cancer (CRC) and hormone-refractory (HRPC) or castration-resistant (CRPC) prostate cancer. Picoplatin is designed to overcome platinum resistance and has the potential for an improved safety profile compared to other platinum-based chemotherapies currently in use.

"We expect that 2009 will be a catalytic year for Poniard, as we expect to complete enrollment in our ongoing registration trial in small cell lung cancer. We believe the results of this trial could support an NDA filing, leading to approval and commercialization of picoplatin in 2010," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We continue to execute our clinical strategy to broaden picoplatin's potential as a platform product. We plan to present clinical data from our other ongoing Phase 2 colorectal and prostate cancer trials at multiple medical conferences. These data, together with picoplatin data in over 750 patients in a broad range of tumor types supports future development and use of picoplatin for the treatment of lung, colorectal, ovarian, prostate, breast, head and neck, bladder, pancreatic and other cancers."

"Poniard is fortunate to have sufficient funding to operate the company into 2010; a management team with a demonstrated ability to bring oncology programs to market; and a Phase 3 oncology product currently on track for initial commercialization in 2010," said Ronald A. Martell, president and COO of Poniard. "We plan to continue to focus our efforts on completing all of the necessary elements that will allow us to prepare and file our NDA. We will also continue to evaluate partnership opportunities that would enable us to maximize picoplatin as a franchise product worldwide."

Poniard plans to work toward the achievement of the following picoplatin goals in 2009:

    Small Cell Lung Cancer
      -- Complete enrollment in the ongoing Phase 3 SPEAR (Study of Picoplatin
         Efficacy After Relapse) trial. This pivotal registration trial is
         evaluating intravenous picoplatin in SCLC patients who have failed or
         relapsed following initial platinum therapy within six months of
         initial treatment. The trial, which is being conducted under a
         Special Protocol Assessment (SPA) from the FDA, is evaluating overall
         survival as the primary endpoint. The FDA also has granted Fast-Track
         status, which may enable an expedited review.
      -- Initiate NDA filing with the U.S. Food and Drug Administration (FDA).


    Colorectal Cancer
      -- Present clinical data from the Phase 2 trial of picoplatin in
         patients with metastatic CRC at the American Society of Clinical
         Oncology's (ASCO) 2009 Gastrointestinal Cancers Symposium on January
         17 in San Francisco. This randomized, controlled trial is evaluating
         picoplatin as a neuropathy-sparing replacement for oxaliplatin for
         the first-line treatment of metastatic CRC in 101 patients who have
         not received prior chemotherapy. The trial is comparing the safety,
         including neuropathy, and efficacy of intravenous picoplatin in
         combination with 5-fluorouracil and leucovorin (the FOLPI regimen) to
         oxaliplatin given in combination with 5-fluorouracil and leucovorin
         in the FOLFOX regimen.
      -- Present updated Phase 2 clinical data, including progression-free and
         overall survival data from this trial, at additional medical
         conferences.
      -- Present final Phase 1 FOLPI clinical data comparing once monthly and
         bi-weekly picoplatin administration at key medical conferences.


    Hormone-Refractory or Castration-Resistant Prostate Cancer
      -- Present data from the ongoing Phase 2 trial of picoplatin in patients
         with metastatic HRPC at ASCO's 2009 Genitourinary Cancers Symposium
         on February 27 in Orlando, Fla. This study is evaluating the efficacy
         and safety of picoplatin administered every three weeks in
         combination with full-dose docetaxel and daily prednisone as a first-
         line treatment in patients with metastatic HRPC or CRPC who have not
         received prior chemotherapy. PSA response (defined as a PSA reduction
         of at least 50 percent from baseline) is the primary endpoint, and
         secondary endpoints include safety, tumor response rate, time to
         progression and overall survival.
      -- Present updated Phase 2 clinical data, including time to disease
         progression and overall survival data, at additional medical
         conferences.


    Oral Picoplatin Program
      -- Present final data from the Phase 1 trial of orally vs. intravenously
         administered picoplatin in patients with advanced solid tumor
         malignancies at medical conferences.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. It is being studied in multiple cancer indications, treatment combinations and in two formulations.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, timing and results of clinical trials, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the period ended September 30, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Announces Upcoming Conference Participation
4. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
5. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
6. MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
7. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
8. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
9. Akrimax Pharmaceuticals Announces Manufacturing Partnership
10. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology: